Graceland Lifescience Corporation Limited

Graceland Lifescience Corporation Limited operates in 7 countries across 4 regions, with Western Europe representing 43% (3 countries) and North America 29% (2 countries). South America and South Asia each account for 14% (1 country each), indicating a strong European presence but limited reach in emerging markets. The concentration in Western Europe and North America suggests a strategy focused on developed, regulated markets, potentially reducing exposure to high-risk or high-growth regions.